RESUMEN
Propylisopropylacetamide (PID) is a chiral CNS-active constitutional isomer of valpromide, the amide derivative of the major antiepileptic drug valproic acid (VPA). The purpose of this work was: a) To evaluate enantiospecific activity of PID on tactile allodynia in the Chung (spinal nerve ligation, SNL) model of neuropathic pain in rats; b) To evaluate possible sedation at effective antiallodynic doses, using the rotorod ataxia test; c) To investigate enantioselectivity in the pharmacokinetics of (R)- and (S)-PID in comparison to (R,S)-PID; and d) To determine electrophysiologically whether PID has the potential to affect tactile allodynia by suppressing ectopic afferent discharge in the peripheral nervous system (PNS). (R)-, (S)- and (R,S)-PID produced dose-related reversal of tactile allodynia with ED(50) values of 46, 48, 42 mg/kg, respectively. The individual PID enantiomers were not enantioselective in their antiallodynic activity. No sedative side-effects were observed at these doses. Following i.p. administration of the individual enantiomers, (S)-PID had lower clearance (CL) and volume of distribution (V) and a shorter half-life (t(1/2)) than (R)-PID. However following administration of (R,S)-PID, both enantiomers had similar CL and V, but (R)-PID had a longer t(1/2). Systemic administration of (R,S)-PID at antiallodynic doses did not suppress spontaneous ectopic afferent discharge generated in the injured peripheral nerve, suggesting that its antiallodynic action is exerted in the CNS rather than the PNS. Both of PID's enantiomers, and the racemate, are more potent antiallodynic agents than VPA and have similar potency to gabapentin. Consequently, they have the potential to become new drugs for treating neuropathic pain.
Asunto(s)
Alilisopropilacetamida/análogos & derivados , Analgésicos/farmacocinética , Evaluación de Medicamentos , Hiperalgesia/metabolismo , Neuralgia/metabolismo , Alilisopropilacetamida/química , Alilisopropilacetamida/farmacocinética , Alilisopropilacetamida/uso terapéutico , Analgésicos/uso terapéutico , Animales , Anticonvulsivantes/uso terapéutico , Área Bajo la Curva , Desnervación Autonómica/métodos , Modelos Animales de Enfermedad , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/etiología , Masculino , Actividad Motora/efectos de los fármacos , Neuralgia/complicaciones , Neuralgia/tratamiento farmacológico , Dimensión del Dolor/métodos , Ratas , Ratas Sprague-Dawley , Estereoisomerismo , Factores de TiempoRESUMEN
The oxidative metabolism of estradiol (the natural estrogen 2,3,5(10)-estratriene-3,17 beta-diol) at positions C-2 and C-16 was examined in primary cultures of chick embryo liver cells using estradiol which was labeled with 3H specifically at either the C-2 or C-16 position as the substrate. Oxidation of estradiol by the cultured liver cells was assessed by the release of 3H which accumulated as 3H2O in the culture medium; both C-2 and C-16 oxidative reactions were detectable in the liver cell cultures by this technique. When incubated with a concentration of estradiol substrate close to the Michaelis constant (Km), approximately 45.8 pmol [2-3H]estradiol and 5.0 pmol [16-3H]estradiol/mg protein per minute underwent oxidative metabolism in untreated cells. Total amounts of oxidized product formation after 2 h of incubation were 28 and 5 pmol/mg protein for C-2 and C-16 oxidation, respectively. Treatment of cultures with phenobarbital or 2-propyl-2-isopropylacetamide significantly increased oxidation at C-16 (1.9-fold and 2.6-fold greater than control values, respectively), whereas no significant change in C-16 oxidation was observed after treatment of the cultures with 3-methylcholanthrene, benzo[a]pyrene, or benz[a]anthracene. The latter chemicals, however, were found to increase the extent of oxidation at C-2 significantly (i.e., 1.5-2.2-fold increases over control values). The increase in C-2 oxidation after treatment of cultures with phenobarbital or 2-propyl-2-isopropylacetamide was significantly less than that observed for oxidation at C-16. The apparent Km values for these oxidations in control cultures were 23.5 and 30.3 microM for C-2 and C-16 oxidation, respectively; corresponding maximum velocity (Vmax) values were 119 and 11.7 pmol/mg protein per minute, respectively. These data indicate that the C-2 and C-16 oxidations of estradiol take place in cultured avian hepatocytes and that the extent of metabolism at these positions on the hormone molecule can be altered by chemicals, such as drugs and polycyclic aromatic hydrocarbons, which induce distinctive species of cytochrome P-450 in the liver.
Asunto(s)
Sistema Enzimático del Citocromo P-450/biosíntesis , Estradiol/metabolismo , Hígado/metabolismo , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Animales , Arocloros/farmacología , Benzoflavonas/farmacología , Recuento de Células , Células Cultivadas , Embrión de Pollo , Hígado/citología , Metilcolantreno/farmacología , Fenobarbital/farmacología , beta-naftoflavonaRESUMEN
Allylisopropylacetamide (AIA) and isopropylvaleramide (IVA) have been demonstrated previously to protect in vivo against the acute toxicity and adrenal necrotic effect of 7,12-dimethylbenz(a)anthracene. In the present study, the influence of these two amides on the in vitro transforming ability of two potent carcinogens, benzo(a)pyrene [B(a)P] and 7,12-dimethylbenz(a)anthracene, on C3H10T1/2 cells was investigated. Both AIA and IVA showed a dose-dependent inhibition of B(a)P-induced transformation of C3H10T1/2 cells when added simultaneously for 24 hr with the carcinogen. While pretreatment, simultaneous treatment, and posttreatment of the cells with AIA or IVA inhibited transformation, the 24-hr posttreatment was somewhat more effective. The protective effect did not appear to results from alterations in B(a)P metabolism inasmuch as aryl hydrocarbon hydroxylase activity and the metabolic products of B(a)P detected by high-pressure liquid chromatography were not changed by AIA or IVA treatment. Furthermore, AIA and IVA did not selectively kill chemically transformed C3H10T1/2 cells, as indicated by the absence of their effect on an established, chemically transformed cell line. AIA and IVA also inhibited 7,12-dimethylbenz(a)anthracene-induced transformation of C3H10T1/2 cells. These data suggest that AIA and IVA may be useful protective agents and that they presumably exert their protective effect at some stage between the activation of the carcinogen and the expression of the transformed phenotype.
Asunto(s)
Acetamidas/farmacología , Alilisopropilacetamida/farmacología , Benzopirenos/antagonistas & inhibidores , Transformación Celular Neoplásica/efectos de los fármacos , 9,10-Dimetil-1,2-benzantraceno/antagonistas & inhibidores , Alilisopropilacetamida/análogos & derivados , Animales , Hidrocarburo de Aril Hidroxilasas/metabolismo , Benzo(a)pireno , Biotransformación/efectos de los fármacos , Células Cultivadas , Ratones , Factores de TiempoRESUMEN
1. Propylisopropyl acetamide (PID) is a new chiral amide derivative of valproic acid. The purpose of this study was to evaluate the anticonvulsant activity of PID in rodent models of partial, secondarily generalized and sound-induced generalized seizures which focus on different methods of seizure induction, both acute stimuli, and following short-term plastic changes as a result of kindling, and to assess enantioselectivity and enantiomer-enantiomer interactions in the pharmacokinetics and pharmacodynamics of racemic PID and its pure enantiomers in rodents. 2. Anticonvulsant activity of (S)-PID, (R)-PID and racemic PID was evaluated in the 6 Hz psychomotor seizure model in mice, in the hippocampal kindled rat, and in the Frings audiogenic seizure susceptible mouse. The pharmacokinetics of (S)-PID and (R)-PID was studied in mice and rats. 3. In mice (S)-PID, (R)-PID and racemic PID were effective in preventing the 6 Hz seizures with (R)-PID being significantly (P < 0.05) more potent (ED(50) values 11 mg kg(-1), 46 mg kg(-1) and 57 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively) than (S)-PID (ED(50) values 20 mg kg(-1), 73 mg kg(-1) and 81 mg kg(-1) at stimulation intensities of 22, 32 and 44 mA, respectively). (S)-PID, (R)-PID and racemic PID also blocked generalized seizures in the Frings mice (ED(50) values 16 mg kg(-1), 20 mg kg(-1) and 19 mg kg(-1) respectively). 4. In the hippocampal kindled rat a dose of 40 mg kg(-1) of (R)- and (S)-PID prevented the secondarily generalized seizure, whereas racemic PID also blocked the expression of partial seizures following an i.p. dose of 40 mg kg(-1). Racemic PID also significantly increased the seizure threshold in this model. 5. Mechanistic studies showed that PID did not affect voltage-sensitive sodium channels or kainate-, GABA- or NMDA- evoked currents. 6. The pharmacokinetics of PID was enantioselective following i.p. administration of individual enantiomers to mice, with (R)-PID having lower clearance and longer half-life than (S)-PID. In rats and mice, no enantioselectivity in the pharmacokinetics of PID was observed following administration of the racemate, which may be due to enantiomer-enantiomer interaction. 7. This study demonstrated that PID has both enantioselective pharmacokinetics and pharmacodynamics. The better anticonvulsant potency of (R)-PID in comparison to (S)-PID may be due to its more favorable pharmacokinetic profile. The enhanced efficacy of the racemate over the individual enantiomers in the kindled rat may be explained by a pharmacokinetic enantiomer-enantiomer interaction in rats. This study also showed the importance of studying the pharmacokinetics and pharmacodynamics of chiral drugs following administration of the individual enantiomers as well as the racemic mixture.
Asunto(s)
Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacocinética , Anticonvulsivantes/farmacocinética , Convulsiones/tratamiento farmacológico , Ácido Valproico/farmacocinética , Alilisopropilacetamida/química , Alilisopropilacetamida/uso terapéutico , Amidas/química , Amidas/farmacocinética , Amidas/uso terapéutico , Animales , Anticonvulsivantes/química , Anticonvulsivantes/uso terapéutico , Células Cultivadas , Corteza Cerebral/citología , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/fisiología , Relación Dosis-Respuesta a Droga , Masculino , Ratones , Ratas , Ratas Sprague-Dawley , Estereoisomerismo , Ácido Valproico/química , Ácido Valproico/uso terapéuticoRESUMEN
The amount of cytochrome P-450 was increased to different extents after treatment of cultured chick embryo hepatocytes with n-propanol, isopropanol, n-butanol, or isobutanol. These increases were associated with increases in benzphetamine demethylase activity, a cytochrome P-450-catalyzed oxidation, and glucuronidation of phenol red, catalyzed by UDP-glucuronyl transferase. The responses were similar to those obtained with ethanol or propylisopropylacetamide, which the phenobarbital-like inducers. Pretreatment of cells with cycloheximide prevented the increases in both cytochrome P-450 and glucuronidation of phenol red, indicating that protein synthesis was required for these responses.
Asunto(s)
Alcoholes/farmacología , Sistema Enzimático del Citocromo P-450/metabolismo , Hígado/enzimología , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Animales , Células Cultivadas , Embrión de Pollo , Cicloheximida/farmacología , Oxigenasas de Función Mixta/metabolismo , Fenolsulfonftaleína/farmacologíaRESUMEN
Cellular glutathione concentrations in primary cultures of chick embryo hepatocytes were 15.3 +/- 5.3 nmoles/mg protein (mean +/- S.D.) and remained stable for up to 3 days in culture. The presence of insulin was not essential for the maintenance of glutathione concentrations. Induction of cytochrome P-450 by phenobarbital-like inducers (2-propyl-2-isopropylacetamide, 2-allyl-2-isopropylacetamide, and 2,4,5,2',4',5'-hexabromobiphenyl) was accompanied by 2- to 3-fold increases in glutathione concentrations and by increased glucuronidation of phenol red. The 3-methylcholanthrene-like inducers of cytochrome P-450 (beta-naphthoflavone and 3,4,3',4'-tetrachlorobiphenyl) did not have these effects. Glutathione was rapidly depleted to 15-30% of control levels in hepatocytes treated with buthionine sulfoximine, an inhibitor of gamma-glutamylcysteine synthase. No toxicity was observed with glutathione depletion. Glutathione depletion did not affect the ability of 2-propyl-2-isopropylacetamide to induce cytochrome P-450, glucuronidation of phenol red, or delta-aminolevulinate synthase.
Asunto(s)
5-Aminolevulinato Sintetasa/biosíntesis , Sistema Enzimático del Citocromo P-450/biosíntesis , Glutatión/análisis , Hígado/análisis , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Animales , Butionina Sulfoximina , Células Cultivadas , Embrión de Pollo , Inducción Enzimática , Glucuronatos/metabolismo , Insulina/farmacología , Metionina Sulfoximina/análogos & derivados , Metionina Sulfoximina/farmacología , Metilcolantreno/farmacología , Fenolsulfonftaleína/metabolismoRESUMEN
Exposure of cultured chick embryo hepatocytes to ethanol, isobutanol, or isopentanol, the predominant alcohols present in commercial alcoholic beverages, resulted in increased metabolism of aminopyrine or biphenyl by the intact cells. The increases correlated with induction of cytochrome P-450. Hydroxylation of biphenyl at the 4-position was preferentially increased in cells pretreated with either the alcohols or propylisopropylacetamide, a barbiturate-like inducer of cytochrome P-450. In contrast, exposure of the cells to 3,4,3',4'-tetrachlorobiphenyl, a planar polycyclic aromatic hydrocarbon inducer of P-450, resulted in preferential increased hydroxylation at the 2- and 3-positions of biphenyl.
Asunto(s)
Alcoholes/farmacología , Aminopirina/metabolismo , Compuestos de Bifenilo/metabolismo , Hígado/metabolismo , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Animales , Butanoles/farmacología , Células Cultivadas , Embrión de Pollo , Sistema Enzimático del Citocromo P-450/metabolismo , Inducción Enzimática/efectos de los fármacos , Etanol/farmacología , Hígado/enzimología , Pentanoles/farmacología , Bifenilos Policlorados/farmacologíaRESUMEN
Propylisopropyl acetamide (PID) and valnoctamide (VCD) are two CNS-active constitutional isomers of valproic acid (VPA) corresponding amide (and prodrug) valpromide. VPA is a major antiepileptic drug (AED) used also in children. Consequently, the purpose of the current study was to see if PID, VCD and two of VCD stereoisomers are active also in juvenile anticonvulsant animal seizure models. Rat pups 7, 12, 18 and 25 days old were pretreated with PID, VCD or the VCD stereoisomers (2S,3S)-VCD, and (2R,3S)-VCD and 30 min later pentetrazol (100mg/kg s.c.) was administered. The incidence of seizures, their expression pattern and their latencies were registered and the severity was expressed by means of a five-point scale. All four tested compounds exhibited anticonvulsant activity against generalized tonic-clonic seizures. Lower doses suppressed specifically the tonic phase in 7-, 12- and 18-day-old rats, while higher doses abolished both phases of generalized seizures. This effect was most pronounced in 12-day-old rats. Twenty-five-day-old rats exhibited suppression of the entire pattern of generalized seizures. There were no significant differences among the drugs used. The CNS-active amide derivatives of VPA, VCD (racemate or individual stereoisomers) and PID exhibit potent anticonvulsant activity against generalized convulsive seizures in developing rats. The majority of these developmental effects are quantitative; while a specific selective action on the tonic phase of generalized seizures is the main qualitative change found in our study.
Asunto(s)
Anticonvulsivantes/farmacología , Convulsivantes , Pentilenotetrazol , Convulsiones/prevención & control , Ácido Valproico/análogos & derivados , Ácido Valproico/farmacología , Envejecimiento/fisiología , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Amidas/farmacología , Animales , Epilepsia Generalizada/inducido químicamente , Epilepsia Generalizada/prevención & control , Masculino , Ratas , Ratas Wistar , Convulsiones/inducido químicamente , EstereoisomerismoAsunto(s)
Hígado/metabolismo , Porfirinas/biosíntesis , 5-Aminolevulinato Sintetasa/biosíntesis , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Células Cultivadas , Medios de Cultivo , Dicarbetoxidihidrocolidina/análogos & derivados , Dicarbetoxidihidrocolidina/farmacología , Inducción Enzimática/efectos de los fármacosAsunto(s)
Acetamidas/farmacología , Alilisopropilacetamida/farmacología , Hexobarbital/farmacología , Hígado/metabolismo , Porfirinas/biosíntesis , Proadifeno/farmacología , 5-Aminolevulinato Sintetasa/biosíntesis , Alilisopropilacetamida/análogos & derivados , Animales , Embrión de Pollo , Pollos/metabolismo , Dicarbetoxidihidrocolidina/farmacología , Interacciones Farmacológicas , Inducción Enzimática/efectos de los fármacos , Hígado/enzimología , Ratas , Especificidad de la Especie , Factores de TiempoAsunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Etanol/farmacología , Hígado/embriología , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Animales , Células Cultivadas , Embrión de Pollo , Relación Dosis-Respuesta a Droga , Glucuronosiltransferasa/metabolismo , Hígado/efectos de los fármacos , Hígado/enzimología , FenolsulfonftaleínaRESUMEN
Propylisopropyl acetamide (PID), an amide analogue of the major antiepileptic drug valproic acid (VPA), possesses favorable anticonvulsant and CNS properties. PID contains one chiral carbon atom and therefore exists in two enantiomeric forms. The purpose of this work was to synthesize the two PID enantiomers and evaluate their enantiospecific teratogenicity. Enantioselective synthesis of PID enantiomers was achieved by coupling valeroyl chloride with optically pure (4S)- and (4R)-benzyl-2-oxazolidinone chiral auxiliaries. The two oxazolidinone enolates were alkylated with isopropyl triflate, hydrolyzed, and amidated to yield (2R)- and (2S)-PID. These two PID enantiomers were obtained with excellent enantiomeric purity, exceeding 99.4%. Unlike VPA, both (2R)- and (2S)-PID failed to exert teratogenic effects in NMRI mice following a single 3 mmol/kg subcutaneous injection. From this study we can conclude that individual PID enantiomers do not demonstrate stereoselective teratogenicity in NMRI mice. Due to its better anticonvulsant activity than VPA and lack of teratogenicity, PID (in a stereospecific or racemic form) has the potential to become a new antiepileptic and CNS drug.
Asunto(s)
Anomalías Inducidas por Medicamentos , Alilisopropilacetamida/análogos & derivados , Anticonvulsivantes/síntesis química , Alilisopropilacetamida/síntesis química , Alilisopropilacetamida/toxicidad , Animales , Anticonvulsivantes/toxicidad , Femenino , Masculino , Ratones , Embarazo , EstereoisomerismoRESUMEN
We examined the effects of the aliphatic amides isopropyl-valeramide (IVA) and allylisopropylacetamide (AIA) on oncogenic transformation and sister chromatid exchanges (SCE) induced by cyclopenta[cd]pyrene (CPP) and benzo[a]pyrene (B[a]P) in C3H/10T1/2 cells and on B[a]Pdiol-epoxide (BPDE)-induced mutation at the HGPRT locus in Chinese hamster ovary (CHO) cells. IVA and AIA significantly suppressed B[a]P and CPP transformation in vitro. Both amides were effective when given just prior to, simultaneously with, or 24 h after carcinogen exposure. On the other hand, IVA and AIA did not affect cytotoxicity, the frequencies of SCE induced by CPP or B[a]P, nor BPDE-induced mutations in CHO cells. These and previous results suggest that the mechanism of inhibition of transformation by IVA or AIA may be very specific and probably not related to the early initiation event in oncogenic transformation in vitro.
Asunto(s)
Acetamidas/farmacología , Alilisopropilacetamida/farmacología , Benzo(a)pireno/toxicidad , Transformación Celular Neoplásica/efectos de los fármacos , Mutación , Pirenos/toxicidad , Intercambio de Cromátides Hermanas/efectos de los fármacos , 7,8-Dihidro-7,8-dihidroxibenzo(a)pireno 9,10-óxido/toxicidad , Alilisopropilacetamida/análogos & derivados , Células Cultivadas , Daño del ADNRESUMEN
We examined the effect of aliphatic amides isopropylvaleramide (IVA) and allylisopropylacetamide (AIA) on the oncogenic transformation of C3H/10T1/2 cells induced by benzo[a]pyrene (B[a]P) or its proximate and ultimate metabolites (+/-)-trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene (B[a]P-7,8-diol) and (+/-)-7 beta,8 alpha-dihydroxy-9 alpha,10 alpha-epoxy-7,8,9, 10-tetrahydrobenzo[a]pyrene (B[a]P-diol-epoxide), respectively. IVA and AIA given prior to, simultaneously with, or for 24 h intervals beginning up to 48 h after removal of carcinogens significantly suppressed transformation induced by B[a]P or the 7,8-diol metabolite. Both modifiers were most effective when added for 24 h immediately following carcinogen exposure. IVA and AIA were also very potent inhibitors of B[a]P-diol-epoxide transformation; however they were most effective when added for 24 h simultaneously with the B[a]P-diol-epoxide. No significant difference in B[a]P-diol-epoxide binding to DNA in C3H/10T1/2 cells was observed during 1 or 24 h exposure to this carcinogen in the presence or absence of IVA or AIA. Neither modifier affected X-ray transformation when added for 24 h immediately following X-irradiation of C3H/10T1/2 cells. These results suggest that AIA and especially IVA might be important tools in studies directed at non-metabolic aspects of B[a]P carcinogenesis.
Asunto(s)
Acetamidas/farmacología , Alilisopropilacetamida/farmacología , Benzo(a)pireno/toxicidad , Transformación Celular Neoplásica/efectos de los fármacos , Dihidroxidihidrobenzopirenos , 7,8-Dihidro-7,8-dihidroxibenzo(a)pireno 9,10-óxido , Alilisopropilacetamida/análogos & derivados , Animales , Benzopirenos/toxicidad , Ratones , Ratones Endogámicos C3HRESUMEN
The growing challenge to secure wholesome food of animal origin in quantities sufficient to feed the ever increasing world population leads to the compelling need of search for new means to enhance animal production. Such an endeavor often involves the use of pharmacologically active agents. As new substances are continuously introduced into agriculture, the necessity clearly arises to reassess the requirements for the approval of compounds likely to appear in the food of man via the edible tissues of animals. Since a number of animal drugs and feed additives have been recently found to show carcinogenic potency, using examples from their own research, the authors discuss problems encountered while planning animal studies for the safety evaluation of chemicals. Among the most important factors to be reckoned with is the metabolism of the test substance. Most carcinogens require metabolic transformation in order to react with macromolecules and, thus, exert their biological action. Similarly, residues of many drugs in animal tissues appear to be various metabolites rather than the parent compounds themselves. At present, it is not known whether many chemical residues are simply stored in different compartments of the carcass as a result of their physico-chemical properties or whether they are covalently bound to vital macromolecules (e.g., nucleic acids). Hence, their biological significance is not quite clear. The enzyme system which metabolizes numerous drugs, pesticides, as well as other endogenous and exogenous substrates is responsible for both the activation and detoxification of carcinogenic chemicals. The delicate balance between these two processes of opposing toxicological consequence is determined by genetic and environmental factors. Depending upon the metabolic profile of chemicals, certain compounds are carcinogenic in one animal species while not in others. The manipulation of their metabolism by physiological (e.g., stress) or pharmacological (e.g., inducers or inhibitors of microsomal enzymes) means can result in a profound change of various biological actions of chemicals (e.g., cytotoxicity, carcinogenicity, mutagenicity). To ascertain that potential toxicological hazards to human health by animal drugs and feed additives will be recognized during the phase of testing, appropriate test animals have to be selected with great care. It is indispensible that the metabolic break-down of the investigational substance proceeds via similar pathways in both test animals and the target species. This will assure that the same metabolites which, in the form of residues in food, man might be exposed to will have ample opportunity to exert their possible adverse effects to the experimental animals during a life-long feeding of the test substance. Therefore, it can, with a reasonable certainty, be assumed that, in experiments performed under such precautionary measures, toxico-pharmacological properties relevant to human safety evaluation will not remain undetected.
Asunto(s)
Fenómenos Fisiológicos Nutricionales de los Animales , Salud Pública , 9,10-Dimetil-1,2-benzantraceno/antagonistas & inhibidores , 9,10-Dimetil-1,2-benzantraceno/toxicidad , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Alimentación Animal , Animales , Biotransformación , Carcinógenos/metabolismo , Técnicas de Cultivo , Duodeno/ultraestructura , Contaminación de Alimentos , Masculino , Ratones , Microscopía Electrónica de Rastreo , Nitrosaminas/toxicidad , Ratas , Espironolactona/farmacología , Esteroides/antagonistas & inhibidores , Esteroides/farmacología , Testículo/ultraestructuraRESUMEN
Hepatic 5-aminolevulinate (ALA) synthase, the first and rate-limiting enzyme in the heme biosynthetic pathway, is known to be feedback repressed by the end product of the pathway, heme. We investigated whether heme regulates ALA synthase mRNA expression transcriptionally or post-transcriptionally in primary cultures of chick embryo hepatocytes. 2-Propyl-2-isopropylacetamide increased the rate of transcription of the ALA synthase gene, whereas heme or an inhibitor of heme biosynthesis, desferrioximine, had no effect on the drug-induced transcription rate. Heme decreased the half-life of ALA synthase mRNA from approximately 3.5 h to 1.2 as recently reported by Drew and Ades (1989, Biochem. Biophys. Res. Commun. 162, 102-107). We also found that the heme-mediated decrease in mRNA stability was prevented by cycloheximide treatment, suggesting that the heme effect was mediated by a labile protein. These results support a model for hepatic ALA synthase regulation in which inducing drugs directly stimulate ALA synthase gene transcription, whereas heme regulates ALA synthase expression post-transcriptionally by modulating mRNA stability as well as by blocking translocation of ALA synthase enzyme into the mitochondrion.
Asunto(s)
5-Aminolevulinato Sintetasa/genética , Hemo/metabolismo , ARN Mensajero/metabolismo , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Animales , Células Cultivadas , Deferoxamina/farmacología , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Semivida , Hemo/farmacología , Hígado/efectos de los fármacos , Hígado/metabolismo , Modelos Biológicos , ARN Mensajero/genética , Transcripción Genética/efectos de los fármacosRESUMEN
Cocaine (COC) causes liver damage in several species, including man. Chicken embryo hepatocyte cultures were evaluated as a model system to investigate the mechanism of cocaine-mediated hepatotoxicity. Parameters used to assess toxicity were: (1) release of lactate dehydrogenase (LDH); (2) decreased induction of 5-aminolevulinic acid synthase (ALAS), measured as porphyrin accumulation; and (3) decreased protein synthesis. Exposure of untreated cultures to COC or norcocaine (NOR) caused dose-dependent increases in LDH release, decreased protein synthesis, and eventual cell death. Pretreatment with 2-propyl-2-isopropylacetamide (PIA), a phenobarbital-like inducer of cytochrome P450, accelerated toxicity and lowered the threshold dose at which toxicity occurred. PIA pretreatment also increased rates of elimination of both COC and NOR and increased rates of formation of NOR from COC. The toxicity of COC and NOR could also be detected as decreased porphyrin accumulation. Addition of the P450 inhibitor SKF-525A concurrently with COC or NOR decreased their rates of elimination. SKF-525A also prevented the increase in LDH release as well as the decrease in protein synthesis caused by treatment with COC or N-hydroxynorcocaine (N-OH). Addition of SKF-525A up to 3 hr after COC resulted in partial prevention of the LDH increase. Exposure of the cultures to COC induced cytochrome P450 2H protein. We conclude that this hepatocyte culture system is highly sensitive to COC toxicity and that constitutive as well as induced cytochrome P450 isoforms are involved in the production of liver damage from COC.
Asunto(s)
Cocaína/toxicidad , Sistema Enzimático del Citocromo P-450/efectos de los fármacos , Hígado/efectos de los fármacos , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Animales , Células Cultivadas , Embrión de Pollo , Cromatografía Líquida de Alta Presión , Cocaína/análogos & derivados , Cocaína/metabolismo , Inducción Enzimática , Immunoblotting , L-Lactato Deshidrogenasa/análisis , Hígado/embriología , Hígado/enzimología , Metilcolantreno/farmacología , Modelos Biológicos , Porfirinas/biosíntesis , Proadifeno/farmacología , Biosíntesis de ProteínasRESUMEN
The effects of inducers of cytochrome P-450 on haem biosynthesis from 5-aminolaevulinate were examined by using cultured chick-embryo hepatocytes. Cultures treated with either 2-propyl-2-isopropylacetamide or 3-methylcholanthrene contained increased amounts of cytochrome P-450 and haem. After treatment for 3 h with 5-amino[4-14C]laevulinate, the relative amounts of radioactivity accumulating as haem corresponded to the relative amounts of total cellular haem, but not to increases in the amounts of cytochrome P-450. Treatment with 5-aminolaevulinate did not alter cellular haem or cytochrome P-450 concentrations in either control or drug-treated cultures. The mechanism of the enhanced accumulation of radioactivity in haem was investigated. Although 2-propyl-2-isopropylacetamide enhanced the uptake of 5-aminolaevulinate and increased the cellular concentration of porphobilinogen 1.5-fold, these changes did not account for the increases in haem radioactivity. The inducing drugs had no effect on the rates of degradation of radioactive haem, but appeared to enhance conversion of protoporphyrin into haem. This latter effect was shown by: (1) a decreased accumulation of protoporphyrin from 5-aminolaevulinate in cells treated with inducers, and (2) complete prevention of this decrease if the iron chelator desferrioxamine was present. We conclude that inducers of cytochrome P-450 may increase haem synthesis not only by increasing activity of 5-aminolaevulinate synthase, but also by increasing conversion of protoporphyrin into haem.
Asunto(s)
Ácido Aminolevulínico/metabolismo , Hemo/biosíntesis , Ácidos Levulínicos/metabolismo , Hígado/metabolismo , Alilisopropilacetamida/análogos & derivados , Alilisopropilacetamida/farmacología , Animales , Células Cultivadas , Embrión de Pollo , Sistema Enzimático del Citocromo P-450/biosíntesis , Deferoxamina/farmacología , Inducción Enzimática/efectos de los fármacos , Hígado/citología , Hígado/efectos de los fármacos , Metilcolantreno/farmacología , Porfobilinógeno/metabolismo , Porfirinas/metabolismoRESUMEN
PURPOSE: The purpose of this study was to evaluate there existed stereoselective effects in the pharmacokinetics, anticonvulsant activity, microsomal epoxide hydrolase (mEH) inhibition, and teratogenicity of the two enantiomers of propylisopropyl acetamide (PID), a CNS-active chiral amide analogue of valproic acid. METHODS: Racemic PID, as well as the individual enantiomers, were intravenously administered to six dogs in order to investigate the stereoselectivity in their pharmacokinetics. Anticonvulsant activity was evaluated in mice (ip) and rats (oral), mEH inhibition studies were performed in human liver microsomes, and teratogenicity was evaluated in an inbred susceptible mice strain. RESULTS: Following intravenous administration to dogs of the individual enantiomers, (R)-PID had significantly lower clearance and longer half-life than (S)-PID, however, the volumes of distribution were similar. In contrast, following intravenous administration of racemic PID, both enantiomers had similar pharmacokinetic parameters. In rats (oral), (R)-PID had a significantly lower ED50 in the maximal electroshock seizure test than (S)-PID; 16 and 25 mg/kg, respectively. PID enantiomers were non-teratogenic and did not demonstrate stereoselective mEH inhibition. CONCLUSIONS: (R)-PID demonstrated better anticonvulsant activity, lower clearance and a longer half-life compared to (S)-PID. When racemic PID was administered, the clearance of (S)-PID was significantly reduced, reflecting an enantiomer-enantiomer interaction.